Terms Of Use | Privacy Policy


Clinical Trials

National Leader in Clinical Trials


In 2014, the Stephenson Cancer Center was selected be one of 30 Lead Academic Participating Sites in the National Cancer Institute's new National Clinical Trials Network. We have continued to establish our presence as a national leader in clinical trials by consistently ranking in the top three cancer centers for patient accruals to Institute-sponsored treatment trials. 

Currently, the Stephenson Cancer center is in the top two cancer centers in the nation for accrual to the MATCH-Trial, the National Cancer Institute's first and most important precision medicine trial.

Learn more about the National Clinical Trials Network >

What is the National Clinical Trials Network?

The National Clinical Trials Network is the result of a major restructuring of cancer research in the United States. The National Cancer Institute, the nation’s largest sponsor of clinical research, established the Network to integrate and streamline the process of cancer clinical trials research with the goal of accelerating the development of promising new cancer therapies and diagnostics for patients.

What are Lead Academic Participating Sites?

Lead Academic Participating Sites provide scientific leadership in the development and conduct of National Cancer Institute clinical trials within the National Clinical Trials Network. This highly-competitive designation is awarded to cancer centers able to demonstrate an outstanding record of developing innovative new clinical trials and enrolling patients to these trials. 

The National Cancer Institute estimates that over half of the patients participating in Institute-sponsored clinical trials will do so at Lead Academic Participating Sites.

What does this mean for Oklahoma cancer patients?

When the Stephenson Cancer Center was selected as a Lead Academic Participating Site in the National Clinical Trials Network, it joined a select group of top cancer centers in the nation. As a Lead Academic Participating Site, the Stephenson will take a lead role in developing new clinical trials for the benefit of cancer patients in Oklahoma. Moreover, the Stephenson Cancer Center will be able to bring to Oklahoma the next generation of precision medicine trials that match promising new cancer drugs with patients based on the unique genotype of their cancer.